Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:04 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Mepolizumab for Eosinophilic Fasciitis
NCT04305678 · Mayo Clinic · PHASE1 · withdrawn · last registry update 2024-11-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Funding lost from Sponsor.” | – | Registry record, Mayo Clinic |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL5 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-09-24Results posted on the registry: McMaster University, Mepolizumab + placebo (NCT01463644)
- 2025-09-17Phase 3 first posted: GlaxoSmithKline, Depemokimab + Placebo (NCT07177339)
- 2025-09-16Results posted on the registry: McMaster University, Mepolizumab + Normal Saline (NCT04765722)
- 2025-09-09Results posted on the registry: GlaxoSmithKline, Depemokimab (GSK3511294) + Placebo (NCT05281523)
- 2025-08-27Results posted on the registry: Mayo Clinic, Nucala (NCT03494881)
- 2025-08-15Results posted on the registry: GlaxoSmithKline, Mepolizumab + Placebo (NCT04133909)
- 2025-05-18Phase 3 first posted: GlaxoSmithKline, Depemokimab (NCT06979323)
- 2025-05-07Phase 3 first posted: GlaxoSmithKline, Depemokimab + Placebo (NCT06961214)
- 2025-05-06Phase 3 first posted: GlaxoSmithKline, Depemokimab + Placebo (NCT06959095)
- 2025-01-14Results posted on the registry: AstraZeneca, Benralizumab + Mepolizumab (NCT04157348)
- 2024-12-17Results posted on the registry: GlaxoSmithKline, GSK3511294 (Depemokimab) + Placebo (NCT04719832)
- 2024-12-10Results posted on the registry: GlaxoSmithKline, Mepolizumab + Salbutamol (NCT04276233)
- 2024-11-29Results posted on the registry: GlaxoSmithKline, GSK3511294 + Placebo (NCT04718103)
- 2024-11-25Results posted on the registry: GlaxoSmithKline, Mepolizumab + Placebo (NCT04607005)
- 2024-09-19Results posted on the registry: GlaxoSmithKline, Mepolizumab 100 milligrams + Placebo (NCT03562195)
- 2024-04-22Results posted on the registry: Food and Drug Administration (FDA), Mepolizumab + Mepolizumab (NCT04183192)
- 2024-04-16Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), mepolizumab (NCT04128371)
- 2024-04-16Also stopped (terminated): National Institute of Allergy and Infectious Diseases (NIAID), mepolizumab (NCT04128371)
- 2024-03-12Results posted on the registry: GlaxoSmithKline, Mepolizumab + Prednisolone (NCT03298061)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision